Moderna (MRNA) Q4 Earnings Watch: Revenue Expected to Drop 31.7% YoY

Moderna (NASDAQ:MRNA) is scheduled to report results Friday, February 14, 2026, before market open. Last quarter, the biotech company posted $1.02 billion in revenue, a 32.2% beat and 45.1% year-over-year decline; it outperformed EPS guidance despite full-year guidance missing expectations. For Q4 2025, analysts expect revenue to fall 31.7% YoY to $660.2 million, versus a 65.6% drop in the same quarter last year, with an adjusted loss of -$2.64 per share. Over the past two years, Moderna has missed revenue estimates only once, outperforming by 30.9% on average. Peer performance provides context: Biogen’s revenue declined 7.1% YoY and beat estimates by 3.6%, while Amgen’s rose 8.6% YoY, exceeding by 4.1%. Biogen rose 4.6% on results; Amgen gained 8.2%. Outlook remains sensitive to trade policy and corporate tax discussions. The therapeutics sector underperformed last month (-2.6% vs. Moderna’s +1.5%); Moderna trades at $40.18 with an average analyst price target of $38.40.